Replies to post #28796 on Curative Biotechnology Inc (CUBT)

[Stock_Barber]

The PRV is not worth $250M... there is no logical basis for that valuation!

* Priority review vouchers are commanding lower and lower prices in recent sales among drugmakers, suggested the once-coveted regulatory "fast pass" may be less attractive as more are issued by the Food and Drug Administration.

* In the latest example, Ultragenyx and Japanese pharma Kyowa Hakko Kirin sold a PRV which they had won in April to an undisclosed buyer for $80.6 million — a far cry from the $350 million AbbVie paid United Therapeutics for one back in 2015. BioCentury first reported the sale Tuesday.

If the TRUTH matters...

https://www.biopharmadive.com/news/ultragenyx-prv-sale-value-regulation-fast-pass/529221/

https://faculty.fuqua.duke.edu/~dbr1/voucher/value